Chemomab Therapeutics awarded new patents for CM-101 in Brazil and Israel

Chemomab Therapeutics announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. Topline data readout expected midyear 2024. The grant of the patent was published January 2, 2024, with corresponding first to expire claims in 2035. PSC is a potentially lethal condition that lacks any FDA-approved therapies and frequently requires liver transplantation.